Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) SEC filings page on Stock Titan provides structured access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, Catalyst uses its filings to report on financial performance, material events, capital allocation decisions, and developments affecting its product portfolio, including FIRDAPSE, AGAMREE, and FYCOMPA.
Investors can review current reports on Form 8-K, where Catalyst discloses events such as quarterly financial results, authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, changes to clinical practice guidelines referencing Lambert-Eaton myasthenic syndrome and amifampridine, and updates to its Board of Directors. These filings often incorporate press releases as exhibits, providing additional context on how specific events may influence the company’s operations and CPRX stock.
In addition to event-driven 8-Ks, users can access periodic reports like Forms 10-Q and 10-K, which contain detailed discussions of product revenue, research and development spending, selling and administrative costs, and other aspects of Catalyst’s business. For a biopharmaceutical issuer, these reports are key resources for understanding revenue contributions from individual products, the status of rare disease programs, and the company’s approach to intellectual property and litigation.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify items such as revenue trends, material agreements, or litigation outcomes. The platform also surfaces insider transaction reports on Form 4 when available, giving additional visibility into trading activity by officers and directors. With real-time updates from EDGAR and simplified explanations of complex regulatory documents, this CPRX filings page supports efficient, in-depth analysis of Catalyst Pharmaceuticals’ regulatory record.
Catalyst Pharmaceutical, Inc. (CPRX) filing a Form 144 notifies the proposed sale of 30,000 common shares through Fidelity Brokerage Services with an aggregate market value of $585,640.54. The shares represent options granted on 12/19/2018 and were acquired on 09/04/2025; payment is expected in cash. The filing lists 122,391,010 shares outstanding and names NASDAQ as the exchange for an approximate sale date of 09/04/2025. It also discloses a recent sale of 20,000 shares by Brian Elsbernd on 09/03/2025 for gross proceeds of $401,514.00. The filer certifies no undisclosed material adverse information.
Catalyst Pharmaceuticals (CPRX) reports a proposed Rule 144 sale of 20,000 common shares, to be transacted through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $401,514.10. The shares were acquired on 09/03/2025 via exercise of options originally granted on 12/19/2018, and payment for those shares is noted as cash. The filing indicates 122,391,010 shares outstanding for the issuer and states there were no securities sold by the reporting person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Insider transaction summary: Director David S. Tierney exercised stock options to acquire 50,000 shares of Catalyst Pharmaceuticals, Inc. common stock at an exercise price of $2.24 per share on 08/27/2025, resulting in 158,274 stock options/underlying derivative securities held following the transaction. To fund the exercise price and estimated taxes, Mr. Tierney sold 26,000 shares in the open market on the same date at a weighted average price of $20.20 per share (sales ranged from $20.10 to $20.32). After these transactions, Mr. Tierney beneficially owned 379,620 shares of common stock. The Form 4 was signed 08/28/2025.
Steve Miller, Chief Operating & Scientific Officer of Catalyst Pharmaceuticals (CPRX), reported option exercises and an open-market sale. On 08/26/2025 he exercised 115,000 options at an exercise price of $2.24 and sold 115,000 shares at a weighted average price of $20.28 (sales ranged $20.04–$20.645) to fund the exercise price and estimated taxes. After those transactions his reported beneficial ownership moved between 1,064,663 and 949,663 shares. On 08/27/2025 he exercised an additional 110,000 options at $2.24. The Form 4 was signed 08/28/2025.
Richard J. Daly, President and CEO and director of Catalyst Pharmaceuticals, reported exercises and a related sale on August 26, 2025. He exercised 50,000 stock options at an exercise price of $2.24 per share, and concurrently sold 22,970 common shares at $20.62 per share to fund the exercise price and tax withholding. Following these transactions, Mr. Daly reported 226,794 shares beneficially owned directly and reported derivative holdings that underlie 50,000 option shares; the filing lists total derivative-related beneficial ownership of 2,184,753 shares.
Catalyst Pharmaceuticals filed an amended current report to correct a naming error in an earlier update about a patent litigation settlement related to its FIRDAPSE® patents. The company had reported a prior settlement with “Inventia Life Science Pty Ltd,” but clarified that the correct party is Inventia Healthcare Limited.
The amendment states that no other terms of the previously disclosed settlement with Lupin or the related press release were changed. Catalyst attached the corrected August 26, 2025 press release as an exhibit, confirming that the update is purely to fix the identity of the earlier settling party.
Catalyst Pharmaceuticals filed a Form 144 notice indicating a proposed sale of 26,000 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $525,087.81. The filing lists the approximate date of sale as 08/27/2025 and names NASDAQ as the securities exchange. It records the number of shares outstanding as 122,391,010. The securities are reported as acquired by an option granted 12/19/2018 with an acquisition date shown as 08/27/2025, and the consideration on sale noted as cash. Several issuer and filer identification fields in the provided content are blank or not shown in the excerpt.
Catalyst Pharmaceuticals (CPRX) Form 144 shows a proposed sale of 115,000 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $2,332,370.02. The filing lists the shares as acquired on 08/26/2025 upon exercise of an option originally granted on 12/19/2018, with the approximate date of sale also listed as 08/26/2025 on the NASDAQ.
The filer certifies no undisclosed material adverse information. No securities were reported sold by the person in the past three months. The notice indicates cash payment for the exercised option and identifies the broker and share count but does not provide the seller's name, percent ownership, or relationship to the issuer.
Catalyst Pharmaceuticals (CPRX) filing a Form 144 notifies the proposed sale of 22,970 common shares by a person for whose account the securities are to be sold, with an aggregate market value of $473,641.40. The shares are held at Fidelity Brokerage Services and the approximate sale date is 08/26/2025 on NASDAQ. The filing shows the shares were acquired on 08/26/2025 pursuant to an option granted on 12/19/2018, and the planned consideration is cash. The filer also reported a prior sale of 70,000 shares on 05/30/2025 generating gross proceeds of $1,740,171.80. The filer attests no undisclosed material adverse information.
Catalyst Pharmaceuticals, Inc. has entered into a settlement agreement with Lupin Ltd. and Lupin Pharmaceuticals, Inc. over patent litigation related to a proposed generic version of FIRDAPSE (amifampridine) 10 mg tablets. Under the agreement, Lupin will not market its generic FIRDAPSE in the United States any earlier than February 25, 2035, if it receives U.S. Food and Drug Administration approval, except in certain limited customary circumstances. All ongoing FIRDAPSE patent litigation between Catalyst, its licensor SERB S.A., and Lupin in the U.S. District Court for the District of New Jersey will be terminated. Catalyst notes that separate FIRDAPSE patent litigation against Hetero covering all Orange Book-listed patents remains ongoing, and there is no assurance that a generic version will be kept off the U.S. market until February 25, 2035.